Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use EBGLYSS safely and effectively. See full prescribing information for EBGLYSS.EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous useInitial U.S. Approval: 2024
Medication labelWhy this: Advisory · dailymed-prescription
EBGLYSS is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.
- generic_name
- lebrikizumab-lbkz
- product_names
- lebrikizumab-lbkz
- ndc
- 0002-7772, 0002-7772-01, 0002-7772-11, 0002-7772-62, 0002-7797, 0002-7797-01, 0002-7797-11, 0002-7797-61
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en